Copyright
©The Author(s) 2020.
World J Clin Cases. Nov 26, 2020; 8(22): 5831-5834
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5831
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5831
Factor | Total 332 patients |
Age in yr, median (range) | 71.9 (19-100) |
Male, n (%) | 178 (59.7) |
BMI in kg/m2, mean (range) | 26.6 (17-42.7) |
Arterial hypertension, n (%) | 97 (29.2) |
Glucose levels in mg/dL, mean (range) | 109.4 (48-505) |
Baseline ALT levels in U/L, median (range) | 39.1 (4-429) |
ALT of > 40 U/L, n (%) | 74 (25.8) |
Baseline AST levels in U/L, mean (range) | 44.7 (7-817) |
ALT of > 60 U/L, n (%) | 82 (28.7) |
Liver cirrhosis, n (%) | 10.0 (3.0) |
Baseline WBC count as × 109/L, mean ± SD | 8.14 ± 6.28 |
Neutrophil count as × 109/L, mean ± SD | 7.37 ± 10.84 |
Lymphocyte count as × 109/L, mean ± SD | 1.54 ± 3.03 |
Lymphocyte count < 1000 as × 109/L, n (%) | 160 (50.3) |
Platelet count as × 109/L, mean ± SD | 227.1 ± 107.5 |
Total bilirubin in mg/dL, mean (range) | 0.79 (0.5-37.0) |
- Citation: Mangia A, Cenderello G, Verucchi G, Ciancio A, Fontana A, Piazzolla V, Minerva N, Squillante MM, Copetti M. Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? World J Clin Cases 2020; 8(22): 5831-5834
- URL: https://www.wjgnet.com/2307-8960/full/v8/i22/5831.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i22.5831